tbuckley/cabot-search huggingface dataset:
FRI0002 Il-1 receptor antagonist (il-1ra) treatment is associated with improvement of anaemia in rheumatoid arthritis
Authors: J Kay, S Bryant, MW Cravets, D McCabe
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Anaemia occurs frequently as an extraarticular complication of rheumatoid arthritis (RA) and usually correlates with markers of disease activity. Interleukin (IL)-1, levels of which are elevated in serum and synovial tissue of patients with RA, inhibits erythropoiesis <i>in vitro</i>. Serum IL-1 levels are higher in anaemic patients with RA than in those without anaemia.<sup>1</sup> <h3>Objectives</h3> To determine if IL-1 receptor antagonist (IL-1ra) is associated with improvement of anaemia in patients with rheumatoid arthritis. <h3>Methods</h3> We observed the effect of daily IL-1ra treatment in anaemic patients with active, severe RA who were enrolled in a 24-week, double-blind, randomised, placebo-controlled multicenter study of IL-1ra therapy. Fifty (14.2%) of the IL-1ra-treated patients and 13 (10.7%) of the placebo-treated patients were anaemic, defined as HCT &lt; = 34%,<sup>2</sup> upon initiation of drug therapy. <h3>Results</h3> Improvement in anaemia was stratified according to the increase after 24 weeks of treatment. Although the number of anaemic patients enrolled in this trial was small, more patients treated with IL-1ra exhibited improvement in HCT after 24 weeks of drug than did patients receiving placebo: <h3>Conclusion</h3> Anaemia improved in patients taking each of the 3 doses of IL-1ra. Interestingly, 3 of the 7 IL-1ra-treated patients with &gt; = 6 vol-% improvement in their HCT did not meet ACR20 response criteria. Thus, IL-1ra therapy may improve anaemia in RA patients independently of its effect on articular disease activity. Further study of IL-1ra therapy in anaemic patients with RA is warranted to clarify its effects on erythropoiesis and the impact of these changes in Hct on clinical status. <h3>References</h3> Maury, <i>et al</i>. Ann Rheum Dis. 1988;47:972 Pincus, <i>et al</i>. Am J Med. 1990;89:161
Immunological aspects of RPE cell transplantation
Authors: Sunao Sugita, Michiko Mandai, Hiroyuki Kamao, Masayo Takahashi
Journal: Progress in Retinal and Eye Research (2021)

Retinal pigment epithelial (RPE) cells have several functions, including support of the neural retina and choroid in the eye and immunosuppression. Cultured human RPE cells directly suppress inflammatory immune cells. For instance, they directly suppress the activation of T cells in vitro. In contrast, transplanted allogeneic human RPE cells are rejected by bystander immune cells such as T cells in vivo. Recently, human embryonic stem cell-derived RPE cells have been used in several clinical trials, and human induced pluripotent stem cell (iPSC)-RPE cells have also been tested in our clinical study in patients with retinal degeneration. Major safety concerns after stem cell-based transplantation surgery include hyper-proliferation, tumorigenicity, or ectopic tissue formation, but these events have currently not been seen in any of these patients. However, if RPE cells are allogeneic, there are concerns about immune rejection issues that have been raised in previous clinical trials. We therefore performed a preclinical study of allogeneic iPSC-RPE cell transplantation in animal rejection models. We then conducted autogenic or allogeneic iPSC-RPE cell transplantation in clinical studies of patients with age-related macular degeneration. In this review, we focus on immunological studies of RPE cells, including iPSC-derived cells. iPSC-RPE cells have unique inflammatory (immunosuppressive and immunogenic) characteristics like primary cultured RPE cells. The purpose of this review is to summarize the current findings obtained from preclinical (basic research) and clinical studies in iPSC-RPE cell transplantation, especially the immunological aspects.
SAT0006 Association of thoracic kyphosis with functional ability, global well-being, and quality of life in ankylosing spondylitis
Authors: A Van Tubergen, S Van der Linden, R Landewé, D Van der Heijde, D Vosse, P Geusens
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To determine the association of increased thoracic kyphosis with functional ability, global well-being, and quality of life in ankylosing spondylitis (AS) patients. <h3>Methods</h3> Baseline data from 120 Dutch AS outpatients participating in a trial on the efficacy of spa therapy were used. Patients were selected on having an occiput-wall distance of 0.0 cm (group A) or an occiput-wall distance &gt; = 10.0 cm (group B), defining no and severe kyphosis respectively. The Bath Ankylosing Spondylitis Functional Index (BASFI) (scale 0–10), Dougados Functional Index (DFI) (scale 0–40) and the Health Assessment Questionnaire for Spondylarthropathies (HAQ-S) (scale 0–3) were used to assess functional ability. Global well-being was assessed with a 10 cm visual analogue scale (scale 0–10), and quality of life with the AS Quality of Life questionnaire (ASQoL) (scale 0–18). For each instrument counts that 0 is the best score. <h3>Results</h3> Group A consisted of 21 patients (9 men, 12 women, mean age 44 (8) years), group B of 26 patients (23 men, 3 women, mean age 51 (10) years). After adjustment for age and gender with multiple regression analysis similar results were found. <h3>Conclusion</h3> An increased occiput-wall distance is associated with deteriorating functional ability. Global well-being and perceived quality of life seem to be generally affected in AS patients, but an increased occiput-wall distance is not associated with further deterioration. The latter merits further investigation.
AB0967 OBESITY IMPACTS SURGICAL REPAIR OF ROTATOR CUFF TEAR IN A LOW-INCOME POPULATION
Authors: C. Silva, N. Mourão, J. Landim, L. Da Rocha, M. Lacerda, A. Rocha
Journal: Annals of the Rheumatic Diseases (2020)

Background: Rotator cuff tears (RCT) rank high among causes of shoulder pain in primary care. Surgical repair of RCT is indicated when judged refractory to clinical treatment. Comorbidities and environmental issues may impact the surgical result of RCT repair. Objectives: to determine the impact of Obesity and Smoking in the outcome of low-income patients subjected to RCT repair. Methods: Low-income (&lt;5500,00 US$ annual pib per capta *) patients living in Fortaleza-CE, Brazil were prospectively (2016-2018) evaluated in the Orthopedic and Rheumatology Services of the Hospital Geral de Fortaleza. Demographics and clinical data focusing Obesity (BMI &gt;/≤ 30) and Smoking status (present/absent) were registered. Pain (0 – 10 cm VAS) and functional shoulder score evaluation by the University of California at Los Angeles Shoulder Score (UCLA) and American Shoulder and Elbow Surgeons (ASES) scoring systems following at least 2 years post-operative follow-up were recorded. Results: Thirty-nine individuals, 60.9±7.1 years-old, 30 female (68.3%) with 5.1 ± 1.9 years follow-up were evaluated; 21 (44.7%) were Smokers and 12 (25.5%) Obese (BMI &gt;30). Other comorbidities included 16 arterial hypertension, 18 dyslipidemia, 17 osteoarthritis, 4 rheumatoid arthritis, 1 gout. Pain VAS values were 5.1 ± 2.6 vs 3.1 ± 2.8 in Obese vs Non-Obese (p=0.03) and 4 ± 2.8 vs 3.37 ± 2.99 in Smokers vs Non-Smokers (p=0.26), respectively. UCLA was 22.4 ± 8.2 vs. 28.79 ± 5.6 in Obese vs Non-Obese (p=0.004) and 26.2 ± 6.5 vs. 27.75 ± 7.18 (p=0.25) in Smokers vs. Non-smokers, respectively. ASES was 47.89 ± 28.3 vs. 68.1 ± 25.78 (p=0.021) in Obese vs. Non-obese and 58.98 ± 26.69 vs 65.3 ± 28.1 (p=0.243) in Smokers vs Non-Smokers, respectively. Conclusion: Using Patient Reported Outcome instruments, these long-term data show that Obesity negatively impacts the outcome of surgical repair of RCT in low-income patients. Smoking status was apparently irrelevant but the number of cigarettes smoked daily was not considered. Emphasis on weight reduction is a practical, affordable though hard to implement measure that could improve surgical results when repairing RCT. References: *https://pt.wikipedia.org/wiki/Lista_de_munic%C3%ADpios_do_Brasil_por_PIB Disclosure of Interests: Christine Silva: None declared, Natalia Mourão: None declared, Joaquim Landim: None declared, Leila da Rocha: None declared, Marco Lacerda: None declared, Airton Rocha Speakers bureau: Not related to the present work
Abstract 17146: In-hospital Outcomes Of Conservative Versus Interventional Therapies For Spontaneous Coronary Artery Dissection
Authors: Paul M Ndunda, Sinan Khayyat, Mohinder Vindhyal, Hayrettin Okut, Job Mogire, Zaher Fanari
Journal: Circulation (2019)

Introduction: Spontaneous coronary artery dissection (SCAD) presents a therapeutic challenge. The optimal therapy remains unknown, but limited data suggest a high complication rate in patients trea...
Health Care Reform—A Historic Moment in US Social Policy
Authors: Elenora E. Connors
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0549 RISK OF INVASIVE FUNGAL INFECTION IN SYSTEMIC LUPUS ERYTHEMATOSUS: A NATIONWIDE POPULATION-BASED STUDY IN TAIWAN
Authors: C. F. Su, C. C. Lai, T. H. LI, Y. F. Chang, Y. T. Lin, C. Y. Tsai, Y. S. Chang
Journal: Annals of the Rheumatic Diseases (2020)

Background: Infectious disease is one of the leading causes of mortality in systemic lupus erythematosus (SLE). Among these infections, invasive fungal infection (IFI) carries high mortality rate (25-70%), but the literature of IFI in SLE is limited. Objectives: To investigate the epidemiology and risk factors of invasive fungal infection and its subtypes, including candidiasis, aspergillosis, and cryptococcosis, in SLE patients. Methods: All patients with newly diagnosed SLE between 1997-2012 were enrolled from Taiwan National Health Insurance Research Database, with an age- and sex-matched non-SLE control group in a ratio of 1:10. IFI was identified by ICD9 codes 1 from discharge record and validated by use of systemic anti-fungal agents. The incidence rate (IR), incidence rate ratio (IRR), cause mortality rate of IFI and its subtypes were compared. A Cox multivariate model with time-dependent covariates was applied to analyse the independent risk factors of IFI. Results: A total of 269 951 subjects (24 541 SLE and 245 410 control) were included. There were 445 episodes of IFI in SLE group. Candida was the most common pathogen (52.8%), followed by cryptococcus and aspergillus. The IR of IFI in SLE was 20.83 per 10,000 person-years with an IRR of 11.1 (95% CI 9.8-12.6) compared to the control (figure 1). Kaplan-Meier curve also disclosed a lower IFI-free survival in SLE (figure 2). The all-cause mortality rate was similar between SLE and the control (26.7 vs 25.7%). In SLE, treatment with mycophenolate mofetil (HR=2.24, 95% CI 1.48-3.37), cyclosporin (HR=1.65, 95% CI 1.10-1.75), cyclophosphamide (HR=1.37, 95% CI 1.07-1.75), oral daily dose of steroid&gt;5 mg prednisolone (HR=1.26, 95% CI 1.01-1.58), and intravenous steroid therapy (HR=29.11, 95% CI 23.30-36.37) were identified as independent risk factors of IFI. Similar analyses were performed for subtypes of IFI. Distinctive risk factors were found between different subtypes of IFI (table 1). Conclusion: SLE patients have a higher risk of IFI. Intravenous steroid therapy is the most important risk factor of IFI. This study provides crucial information for risk stratification of IFI in SLE. References: [1] Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015 Dec; 74(12):2107-2116. Disclosure of Interests: None declared
Deep COVID DeteCT: an international experience on COVID-19 lung detection and prognosis using chest CT
Authors: Edward H. Lee, Jimmy Zheng, Errol Colak, Maryam Mohammadzadeh, Golnaz Houshmand, Nicholas Bevins, Felipe Kitamura, Emre Altinmakas, Eduardo Pontes Reis, Jae-Kwang Kim, Chad Klochko, Michelle Han, Sadegh Moradian, Ali Mohammadzadeh, Hashem Sharifian, Hassan Hashemi, Kavous Firouznia, Hossien Ghanaati, Masoumeh Gity, Hakan Doğan, Hojjat Salehinejad, Henrique Alves, Jayne Seekins, Nitamar Abdala, Çetin Atasoy, Hamidreza Pouraliakbar, Majid Maleki, S. Simon Wong, Kristen W. Yeom
Journal: npj Digital Medicine (2021)

The Coronavirus disease 2019 (COVID-19) presents open questions in how we clinically diagnose and assess disease course. Recently, chest computed tomography (CT) has shown utility for COVID-19 diagnosis. In this study, we developed Deep COVID DeteCT (DCD), a deep learning convolutional neural network (CNN) that uses the entire chest CT volume to automatically predict COVID-19 (COVID+) from non-COVID-19 (COVID-) pneumonia and normal controls. We discuss training strategies and differences in performance across 13 international institutions and 8 countries. The inclusion of non-China sites in training significantly improved classification performance with area under the curve (AUCs) and accuracies above 0.8 on most test sites. Furthermore, using available follow-up scans, we investigate methods to track patient disease course and predict prognosis.
Effectiveness of a specialised breathlessness service for patients with advanced disease in Germany: a pragmatic fast-track randomised controlled trial (BreathEase)
Authors: Michaela Schunk, Lien Le, Zulfiya Syunyaeva, Birgit Haberland, Susanne Tänzler, Ulrich Mansmann, Larissa Schwarzkopf, Hildegard Seidl, Sabine Streitwieser, Miriam Hofmann, Thomas Müller, Tobias Weiß, Philipp Morawietz, Eva Annette Rehfuess, Rudolf Maria Huber, Ursula Berger, Claudia Bausewein
Journal: European Respiratory Journal (2021)

The effectiveness of the Munich Breathlessness Service (MBS), integrating palliative care, respiratory medicine and physiotherapy, was tested in the BreathEase trial in patients with chronic breathlessness in advanced disease and their carers.BreathEase was a single-blinded randomised controlled fast-track trial. The MBS was attended for 5-6 weeks; the control group started the MBS after 8 weeks of standard care. Randomisation was stratified by cancer and the presence of a carer. Primary outcomes were patients' mastery of breathlessness (Chronic Respiratory Disease Questionnaire (CRQ) Mastery), quality of life (CRQ QoL), symptom burden (Integrated Palliative care Outcome Scale (IPOS)) and carer burden (Zarit Burden Interview (ZBI)). Intention-to-treat (ITT) analyses were conducted with hierarchical testing. Effectiveness was investigated by linear regression on change scores, adjusting for baseline scores and stratification variables. Missing values were handled with multiple imputation.92 patients were randomised to the intervention group and 91 patients were randomised to the control group. Before the follow-up assessment after 8 weeks (T1), 17 and five patients dropped out from the intervention and control groups, respectively. Significant improvements in CRQ Mastery of 0.367 (95% CI 0.065-0.669) and CRQ QoL of 0.226 (95% CI 0.012-0.440) score units at T1 in favour of the intervention group were seen in the ITT analyses (n=183), but not in IPOS. Exploratory testing showed nonsignificant improvements in ZBI.These findings demonstrate positive effects of the MBS in reducing burden caused by chronic breathlessness in advanced illness across a wide range of patients. Further evaluation in subgroups of patients and with a longitudinal perspective is needed.
Histone Ubiquitination: An Integrative Signaling Platform in Genome Stability
Authors: Francesca Mattiroli, Lorenza Penengo
Journal: Trends in Genetics (2021)

Complex mechanisms are in place to maintain genome stability. Ubiquitination of chromatin plays a central role in these mechanisms. The ever-growing complexity of the ubiquitin (Ub) code and of chromatin modifications and dynamics challenges our ability to fully understand how histone ubiquitination regulates genome stability. Here we review the current knowledge on specific, low-abundant histone ubiquitination events that are highly regulated within the cellular DNA damage response (DDR), with particular emphasis on the latest discovery of Ub phosphorylation as a novel regulator of the DDR signaling pathway. We discuss players involved and potential implications of histone (phospho)ubiquitination on chromatin structure, and we highlight exciting open questions for future research.
Systemic therapy with a loco-regional treatment in patients with locally advanced pancreatic cancer: The SMART study.
Authors: Shahid Ahmed, Osama Ahmed, Deborah Anderson, Gavin Beck, Haji I. Chalchal, Lynn Dwernychuk, Josh Gitlin, Austin Hammond, Mussawar Iqbal, June Lim, Sukanya Pati, Nazmi Sari, John Shaw, Osama Souied, Christopher Wall, Adnan Zaidi, Michael Moser
Journal: Journal of Clinical Oncology (2021)

TPS445 Background: Pancreatic cancer is a major cause of cancer-related death. About 40% of patients with pancreatic cancer present with locally advanced disease and are not candidates for curative surgery. Most patients are treated with chemotherapy with a limited life expectancy. The role of local treatment such as radiation is not well defined. Other conventional ablative therapies, such as thermal or cryoablation have limited role due to the risk of collateral damage to the adjacent structures. Irreversible electroporation (IRE) is a novel non-thermal ablation technology that does not cause injury to nearby blood vessels, ducts, and bowel and has the potential to provide longer disease control and thereby better overall survival. We hypothesized that addition of IRE to combination chemotherapy in patients with locally advanced pancreatic cancer will improve their outcomes, and patients with undetectable 12-week post IRE circulating tumor cell DNA will have better prognoses. Methods: It is a prospective, multicenter, single-arm phase II study. The primary objective is to determine 12-month PFS rate of patients with locally advanced pancreatic cancer who are treated with combination chemotherapy and IRE. Secondary objectives include identification of prognostic and predictive biomarkers, 24-months survival rate, quality of life of subjects, as well as cost-effectiveness and complication rates of IRE. Based on the assumption that treatment with IRE and chemotherapy would result in doubling of PFS versus chemotherapy alone a sample of n = 27 of patients with locally advanced pancreatic adenocarcinoma is estimated. Eligible patients will be recruited at the two major cancer centers in Saskatchewan. All IRE-eligible patients will receive 12 weeks of induction combination chemotherapy and will undergo IRE if there is no disease progression. An additional 12 weeks of chemotherapy will be recommended. Patients who are not eligible for IRE will receive chemotherapy at the discretion of treating oncologist until disease progression or until they become eligible for IRE. Circulating tumor DNA and a panel of genes will be examined using next-generation sequencing for their correlation with prognosis. Quality of life will be assessed, and cost-effectiveness analysis of IRE will be performed.The results of this study will be used to develop a future multicenter, national phase III trial. Clinical trial information: NCT04276857.
AB0170 The simvastatin effect on osteoporosis
Authors: S Sokolovic, F Gavrankapetanovic, V Gerc, A Arslanagic, M Kulic
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> The Osteoporosis has always been a great problem for the clinicians in every country, since this disorder brings higher morbidity, disability and mortality. The Statins, lipid lowering drugs, have been recently shown to have positive impact on the osteoporosis, i.e. the bone mineral density, where the "T" score has increased in patients taking these drugs for hiperlipidemia. <h3>Objectives</h3> The objective of this research is to investigate the potential efficiency of Simvastatin (Lipex) on BMD score i.e. T score in patients suffering from postmenopausal osteoporosis. <h3>Methods</h3> An open randomised Prospective Control Study has been designed. The patients with the postmenopausal osteoporosis have been selected in one group and they received lipex 10 mg plus 500 Calcium at bed time. The other group of potmenopausal women, served as the control one, was assigned to receive only 500 mg of Calcium at the evening meal. Total number of individuals in each group was thirty three. Laboratory test including the risk factor stratifications were detected on baseline and after 3. The statistical analysis was done between two groups. <h3>Results</h3> The results obtained in this study showed the significant improvement in the group of patients receiving lipex and the score is much higher than those taking calcium only. This BMD result, i.e. T score, has been found to be about 30% higher in simvastatin group. The positive effect on lipid profile has been gained as well. The well-being improvement has also been notified. <h3>Conclusion</h3> The statins, in our research simvastatin (lipex), has been proven in our study to have a very positive effect on the treatment of osteoporosis. So, beside the primary effect of statins on lowering cholesterol levels, this is the other option and positivity of this drug. These medications can be added to the list of therapy in osteoporosis.
急性冠症候群患者における血管内超音波Virtual histology imagesおよびフィルターデバイスにより捕獲された物質の病理学的解析
Authors: Matsubara Takao, Sakata Kenji, Uno Yoshihide, Yasuda Toshihiko, Miwa Kenji, Inoue Masaru, Kanaya Honin, Kurumaya Hiroshi, Kawashiri Masaaki, Tada Hayato, Ino Hidekazu, Yamagishi Masakazu
Journal: Circulation (2008)